Evidence map›Paper›PMID 42249874›Full record

ArticleJACC. Case reports2026

Phenotypic Spectrum of Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis.

Zoha Majeed, Alexandra S Manaila, Bo Xu, Karlee Hoffman, Andres Carmona Rubio, Heba Wassif, Alexandra Villa Forte, Maria Mountis, Arianne Clare C Agdamag

Abstract readCase Reports
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zoha MajeedDepartment of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Alexandra S ManailaDepartment of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Bo XuSection of Cardiac Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Karlee HoffmanSection of Heart Failure and Transplantation, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Andres Carmona RubioSection of Heart Failure and Transplantation, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Heba WassifSection of Clinical Cardiology & Director of Cardio-rheumatology, Department of Cardiovascular Medicine, Miller Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Alexandra Villa ForteDepartment of Rheumatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Maria MountisSection of Heart Failure and Transplantation, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Arianne Clare C AgdamagSection of Heart Failure and Transplantation, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. Electronic address: AGDAMAA@CCF.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) is a major determinant of morbidity and mortality and may occur independently of systemic disease activity. CASE SUMMARY: We describe 3 patients with EGPA demonstrating distinct cardiac phenotypes. Patient presentation included: 1) inflammatory cardiomyopathy with severe biventricular dysfunction that improved following escalation of immunosuppression and guideline-directed medical therapy; 2) advanced nonischemic cardiomyopathy and cardiogenic shock requiring temporary and durable mechanical circulatory support, representing an irreversible fibrotic phenotype; and 3) relapsing-remitting eosinophilic perimyocarditis and recurrent ventricular dysfunction despite multiple immunosuppressive regimens. Cardiac magnetic resonance imaging and hemodynamic assessment were central to phenotypic classification and management. DISCUSSION: EGPA cardiomyopathy exists along a spectrum from reversible inflammatory myocarditis to advanced fibrotic remodeling. Cardiac involvement may progress despite improvement in systemic manifestations and is not reliably predicted by antineutrophil cytoplasmic antibody status. TAKE-HOME MESSAGE: Phenotype-based assessment and longitudinal cardiac surveillance may guide immunosuppressive strategies and prognosis in EGPA cardiomyopathy.

Indexed as

cardiac magnetic resonancecardiomyopathychronic heart failurehemodynamics

Identifiers

PMID42249874
PMCPMC13464258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.